title: Different serum anti-Müllerian hormone concentrations are associated with oocyte quality, embryo development parameters and IVF-ICSI outcomes.
abstract: OBJECTIVE
  To evaluate the association between different basal serum levels of anti-Müllerian hormone (AMH) and oocyte-embryo quality and IVF outcomes.
  
  
  METHODS
  Two hundred and nine infertile women who underwent in vitro fertilization treatment with intracytoplasmic sperm injection (ICSI) between January 2009 and February 2011 were included in the study. Mean age, BMI, FSH, E(2), inhibin B, duration of infertility, total gonadotropin dose, antral follicle count, morphology of all oocytes, percentage of MII, early cleavage rate, the number of good quality embryos in transfer and ongoing pregnancy (>12 weeks) rates were evaluated.
  
  
  RESULTS
  Six groups were formed according to the percentiles as <10% (≤0.89 ng/ml; n = 21), 10-25% (0.89-1.40 ng/ml; n = 31), 25-50% (1.40-2.89 ng/ml; n = 53), 50-75% (2.89-4.83 ng/ml; n = 28), 75-90% (4.83-8.06 ng/ml; n = 55), >90% (>8.06 ng/ml; n = 21). Central granulation, cytoplasmic granulation, oocyte postmaturity, percentage of embryos, early cleavage and percentage of transferred good quality embryos were significantly different in five groups (ANOVA test). Ongoing pregnancy rate (PR) was the lowest in <10% (9.5%), and the highest in 50-75% group (39.3%). (P = 0.040)
  
  
  CONCLUSIONS
  Different AMH levels may predict the quality of oocytes, presence of postmaturity and nucleoli Z score, early cleavage and ICSI outcomes.
authors: Department of Obstetrics and Gynecology, Cerrahpasa School of Medicine, Istanbul University, IVF Unit, Istanbul, Turkey.
authors: Tulay
authors: T
authors: Irez
authors: Pelin
authors: P
authors: Ocal
authors: Onur
authors: O
authors: Guralp
authors: Meral
authors: M
authors: Cetin
authors: Begum
authors: B
authors: Aydogan
authors: Sezai
authors: S
authors: Sahmay
mesh_terms: D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood*; D015992:Body Mass Index; D047108:Embryonic Development / Q000187:drug effects; D004958:Estradiol / Q000097:blood; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage; D006062:Gonadotropins / Q000008:administration & dosage; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000628:therapy; D007265:Inhibins / Q000097:blood; D016729:Leuprolide / Q000008:administration & dosage; D009865:Oocytes / Q000187:drug effects / Q000254:growth & development*; D006080:Ovarian Follicle / Q000187:drug effects; D010062:Ovulation Induction; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D020554:Sperm Injections, Intracytoplasmic; D016896:Treatment Outcome
chemical_list: D005300:Fertility Agents, Female; D006062:Gonadotropins; C422364:inhibin B; D004958:Estradiol; D007265:Inhibins; D054304:Anti-Mullerian Hormone; D016729:Leuprolide